Skip to main content

Table 1 Baseline characteristics (intention-to-treat population; n=481)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Characteristic Aged 41–50 years (n=327) Aged >50 years (n=154)
Females, % 72.7% 66.9%
Ethnicity:
  Caucasian 74.6% 73.4%
  Black 2.1% 0.0%
  Hispanic 6.7% 4.5%
  Asian 8.9% 16.2%
  other 7.6% 5.8%
Age at study baseline, mean years (SD) 45.1 (2.8) 56.2 (4.2)
Age at onset of clinical symptoms, mean years (SD) 41.6 (5.9) 50.7 (7.5)
RRMS, %a 96.3% 94.9%
SPMS, %b 3.7% 5.1%
MS duration since onset of symptoms, mean years (SD) 3.9 (5.2) 5.9 (7.1)
Relapses during last 2 years,a mean number (SD) 1.7 (1.0) 1.6 (1.1)
≥2 relapses during last 2 years,a % 55.6% 52.7%
EDSS, mean (SD) 2.5 (1.5) 3.1 (1.9)
EDSS ≥3, % 41.6% 52.0%
Cranial MRI performed, % 96.3% 94.0%
Contrast-enhancing lesions, % 28.8% 22.7%
DMT use prior to BEACON, % 14.1% 13.6%
  1. aBefore study entry.
  2. bThe percentages for patients with RRMS and SPMS are based on a total of 411 patients with confirmed MS (273 patients in those aged 41–50years, and 138 in those aged >50 years).
  3. BEACON Betaferon prospective study on adherence, coping and nurse support; DMT disease-modifying therapy; EDSS expanded disability status scale; MRI magnetic resonance imaging; RRMS relapsing–remitting multiple sclerosis; SD standard deviation; SPMS secondary progressive multiple sclerosis